In a report released today, Gil Blum from Needham reiterated a Buy rating on Celcuity (CELC – Research Report), with a price target of $25.00. The company's shares closed last Monday at $9.25. According to TipRanks.com, Blum 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -13.5% and a 35.2% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Aeglea Biotherapeutics, and Rocket Pharmaceuticals. Celcuity has an analyst consensus of Moderate Buy, with a price target consensus of $22.50.
https://www.tipranks.com/news/blurbs/needham-keeps-their-buy-rating-on-celcuity-celc?utm_source=advfn.com&utm_medium=referral
Celcuity (NASDAQ:CELC)
Gráfico Histórico do Ativo
De Ago 2022 até Set 2022 Click aqui para mais gráficos Celcuity.
Celcuity (NASDAQ:CELC)
Gráfico Histórico do Ativo
De Set 2021 até Set 2022 Click aqui para mais gráficos Celcuity.